POM vs DOCS

For growth investors, Doximity, Inc.

(DOCS) is the stronger pick with 20. 0% revenue growth year-over-year, versus 12. 4% for POMDOCTOR Ltd (POM). Doximity, Inc. (DOCS) offers the better valuation at 23. 5x trailing P/E (16. 8x forward), making it the more compelling value choice. Analysts rate Doximity, Inc. (DOCS) a "Buy" — based on 22 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Doximity, Inc.

(DOCS) delivered a total return of -50. 9%, compared to -86. 8% for POMDOCTOR Ltd (POM). Over 10 years, the gap is even starker: DOCS returned -50. 9% versus POM's -86. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Doximity, Inc.

(DOCS) is the lower-risk stock at 1. 03β versus POMDOCTOR Ltd's 1. 45β — meaning POM is approximately 41% more volatile than DOCS relative to the S&P 500.

By revenue growth (latest reported year), Doximity, Inc.

(DOCS) is pulling ahead at 20. 0% versus 12. 4% for POMDOCTOR Ltd (POM). On earnings-per-share growth, the picture is similar: Doximity, Inc. grew EPS 54. 2% year-over-year, compared to 1. 6% for POMDOCTOR Ltd. Over a 3-year CAGR, DOCS leads at 18. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Doximity, Inc.

(DOCS) is the more profitable company, earning 39. 1% net margin versus -41. 9% for POMDOCTOR Ltd — meaning it keeps 39. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DOCS leads at 39. 9% versus -7. 5% for POM. At the gross margin level — before operating expenses — DOCS leads at 90. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Doximity, Inc.

(DOCS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 03)). Both have compounded well over 10 years (DOCS: -50. 9%, POM: -86. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: POM is a small-cap quality compounder stock; DOCS is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.